Records containing: NASH
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-06-02A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)
-
CLINICAL_TRIALS study record update · 2026-04-17Prospective Cohort Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
-
CLINICAL_TRIALS study record update · 2026-04-13Androgens and Nonalcoholic Fatty Liver Disease (NAFLD) In Reproductive-Aged Women With and Without Polycystic Ovary Syndrome (PCOS)
-
CLINICAL_TRIALS study record update · 2026-04-09PRObiotic Mixed With Exercise THErapy USe in MAFLD (PROMETHEUS in MAFLD)
-
CLINICAL_TRIALS study record update · 2026-04-08Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-08A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Treatment With DD01 for 48 Weeks in Overweight/Obese Subjects With MASLD/MASH
-
CLINICAL_TRIALS study record update · 2026-03-27Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Participants With Noncirrhotic Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
-
CLINICAL_TRIALS study record update · 2026-03-13A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Non-alcoholic Steatohepatitis (NASH).
-
CLINICAL_TRIALS study record update · 2026-03-11Feasibility Study for Quantifying Fatty Liver Using Thermo-acoustic Imaging
-
CLINICAL_TRIALS study record update · 2025-12-17An Imaging-based Quantitative Biomarker Assay for Non-alcoholic Fatty Liver Disease (NAFLD) in Children: a Feasibility Study
-
CLINICAL_TRIALS study record update · 2025-11-20Study for the Evaluation of Risk of hEpatocellular Carcinoma in NonAlcoholic Fatty Liver
-
CLINICAL_TRIALS study record update · 2025-11-18Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus
-
CLINICAL_TRIALS study record update · 2025-10-31Clinical Trial of Oral Digoxin In NASH (CODIN)
-
CLINICAL_TRIALS study record update · 2025-09-22A Phase I, Two Parts Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of BAR502 in Healthy Subjects
-
CLINICAL_TRIALS study record update · 2025-08-14Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study
-
CLINICAL_TRIALS study record update · 2025-07-25Efficacy of a Novel Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD
-
CLINICAL_TRIALS study record update · 2025-07-20An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease
-
CLINICAL_TRIALS study record update · 2025-06-11A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)
-
CLINICAL_TRIALS study record update · 2025-05-15A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis (MASH) and F2/F3 Fibrosis (FASCINATE-3)
-
CLINICAL_TRIALS study record update · 2025-05-15A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
CLINICAL_TRIALS study record update · 2025-04-16Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & Validation of Imaging Modality Performance Across the NAFLD Spectrum in a Prospectively Recruited Cohort
-
CLINICAL_TRIALS study record update · 2025-03-21Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease by Integration of Artificial Intelligence Model and omicS Data
-
CLINICAL_TRIALS study record update · 2025-03-17Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease
-
CLINICAL_TRIALS study record update · 2025-02-17A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index
-
CLINICAL_TRIALS study record update · 2025-02-17A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALG-055009 in Non-Cirrhotic Adults With Metabolic Dysfunction-Associated Steatohepatitis